CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more
CHA Biotech Co. Ltd (085660) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.002x
Based on the latest financial reports, CHA Biotech Co. Ltd (085660) has a cash flow conversion efficiency ratio of -0.002x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.24 Billion) by net assets (₩760.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CHA Biotech Co. Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how CHA Biotech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CHA Biotech Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CHA Biotech Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TV Asahi Holdings Corporation
PINK:THDDY
|
0.011x |
|
Keboda Technology Co Ltd
SHG:603786
|
0.047x |
|
PT Indosat Tbk
PINK:PTITF
|
0.097x |
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
0.011x |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
-0.246x |
|
MONGOLIAN MINING CRP.REGS
F:29X2
|
N/A |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
-0.080x |
|
SANGETSU CO LTD
OTCGREY:SGSUF
|
N/A |
Annual Cash Flow Conversion Efficiency for CHA Biotech Co. Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of CHA Biotech Co. Ltd from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩284.69 Billion | ₩-49.55 Billion | -0.174x | -1092.29% |
| 2023-12-31 | ₩656.33 Billion | ₩11.51 Billion | 0.018x | +124.80% |
| 2022-12-31 | ₩291.73 Billion | ₩-20.63 Billion | -0.071x | -245.08% |
| 2021-12-31 | ₩456.06 Billion | ₩22.23 Billion | 0.049x | -63.17% |
| 2020-12-31 | ₩355.09 Billion | ₩47.00 Billion | 0.132x | +97.78% |
| 2019-12-31 | ₩377.18 Billion | ₩25.24 Billion | 0.067x | -70.97% |
| 2018-12-31 | ₩326.99 Billion | ₩75.38 Billion | 0.231x | +342.94% |
| 2017-12-31 | ₩230.74 Billion | ₩12.01 Billion | 0.052x | +31.95% |
| 2016-12-31 | ₩286.32 Billion | ₩11.29 Billion | 0.039x | -81.50% |
| 2015-12-31 | ₩290.10 Billion | ₩61.86 Billion | 0.213x | +3732.73% |
| 2014-12-31 | ₩437.45 Billion | ₩-2.57 Billion | -0.006x | -104.53% |
| 2013-12-31 | ₩512.34 Billion | ₩66.35 Billion | 0.130x | -6.23% |
| 2012-12-31 | ₩331.41 Billion | ₩45.77 Billion | 0.138x | +13.63% |
| 2011-12-31 | ₩285.46 Billion | ₩34.69 Billion | 0.122x | -54.29% |
| 2010-12-31 | ₩158.24 Billion | ₩42.07 Billion | 0.266x | +39.05% |
| 2009-12-31 | ₩125.61 Billion | ₩24.02 Billion | 0.191x | -- |